Evoke Pharma, Inc.
(EVOK)
Add Watchlist
0.47 USD +0.01
Closed: 17 May, 3:55 pm
Symbol EVOK
Market Cap 3.9M
Price 0.47
Open 0.47
52-wk High 2.16
50 Day Avg 0.54
Earnings Announcement 2024-08-08
Website https://www.evokepharma.com
Name Evoke Pharma, Inc.
Shares Outstanding 8,597,410
Change % 0.6276%
Low 0.46
52-wk Low 0.41
200 Day Avg 0.94
Last Dividend 0.00
Exchange NASDAQ
Volume 21,408
Previous Close 0.46
High 0.50
EPS -2.33
PE -0.20
Avg Volume 32,103
CUSIP 30049G104
Evoke Pharma, Inc. Outlook
Description Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Currency USD
ISIN US30049G2030
Industry Drug Manufacturers - Specialty & Generic
Changes 0.00
CUSIP 30049G104
Range 0.41 - 2.16
Beta 0.38
CIK 0001403708

Evoke Pharma, Inc. News

16-May-2024 4:02 PM

Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference

SOLANA BEACH, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.  (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that its abstract demonstrating enhanced gastroparesis care in women using nasal metoclopramide will be presented at the 2024 Digestive Disease Week Conference (DDW 2024) taking place May 18-21, 2024 in Washington D.C.

14-May-2024 4:15 PM

Evoke Pharma Reports First Quarter 2024 Financial Results

114% year-over-year increase in net product sales 70% prescriber growth in Q1 2024 compared to Q4 2023 Growing sales metrics reaffirms company's $14M net revenue guidance for 2024

17-Apr-2024 8:30 AM

Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications

Michael Cline, DO., Medical Director Gastroparesis Clinic, Cleveland Clinic to present Michael Cline, DO., Medical Director Gastroparesis Clinic, Cleveland Clinic to present

21-Mar-2024 4:15 PM

Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer

SOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that Matthew J. D'Onofrio will be succeeding David A. Gonyer as Chief Executive Officer as of March 31, 2024 upon Mr. Gonyer's departure for personal reasons. Mr. D'Onofrio currently serves as President and Chief Operating Officer.

14-Mar-2024 9:33 PM

Evoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call Transcript

Evoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call Transcript

14-Mar-2024 4:05 PM

Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results

Fiscal year 2023 net product sales from prescriptions totaled approximately $5.2M, a 107% increase from 2022

07-Mar-2024 4:10 PM

Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024

SOLANA BEACH, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, today announced that the Company is scheduled to release its fourth quarter and full year 2023 on Thursday, March 14, 2024, after the market closes.

14-Feb-2024 7:30 AM

Evoke Pharma Announces Closing of $7.5 Million Public Offering

Potential for Additional $22.5 Million in the Event of Exercise of Common Warrants in Full Potential for Additional $22.5 Million in the Event of Exercise of Common Warrants in Full

09-Feb-2024 7:30 AM

Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million

SOLANA BEACH, Calif., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced today that it has priced an underwritten public offering led by Nantahala Capital Management, with participation by other fundamental investors, for gross proceeds of up to $30 million, that includes initial upfront funding of approximately $7.5 million, prior to deducting underwriting discounts and commissions and estimated offering expenses.

29-Jan-2024 9:00 AM

Kestra Private Wealth Services Announces New Partnership Between Maven Bridge Capital and Evoke Wealth Management

AUSTIN, Texas--(BUSINESS WIRE)--Kestra Private Wealth Services Announces New Partnership Between Maven Bridge Capital and Evoke Wealth Management.

27-Nov-2023 8:30 AM

Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent

SOLANA BEACH, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that its recently issued U.S. patent related to GIMOTI, No.